<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Moderna and BioNTech pioneered mRNA vaccines. But who will make a mark in therapeutics? — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Moderna and BioNTech pioneered mRNA vaccines. But who will make a mark in therapeutics?</h2>
    <div class="badge">2025-09-15T08:00:00+00:00</div>
    <ul>
      <li>Moderna, which continues its work on vaccines, recently announced plans to lay off 10% of its workforce following the dip in COVID-relarted demand and lackluster sales of its RSV vaccine.</li>
<li>The FDA granted the phase 2 candidate fast track status.</li>
<li>HHS also recently deprioritized mRNA vaccine development, pulling $500 million in funding from projects, and voicing support for a shift to other vaccine platforms.</li>
<li>The company recently secured $153 million in series B funding, even amid a significant contraction in biotech investment, showing enthusiasm for the platform, Becraft said.</li>
<li>Over the next 10 to 15 years, this could lead to expanded opportunities with other companies.</li>
<li>It’s also testing the drug in phase 2 kidney cancer and bladder cancer, among others, according to a second-quarter update.</li>
<li>In May, Strand released promising interim phase 1 results for its lead candidate STX-001 in melanoma and other solid tumors.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Moderna and BioNTech pioneered mRNA vaccines. But who will make a mark in therapeutics?\n• Moderna, which continues its work on vaccines, recently announced plans to lay off 10% of its workforce following the dip in COVID-relarted demand and lackluster sales of its RSV vaccine.\n• The FDA granted the phase 2 candidate fast track status.\n• HHS also recently deprioritized mRNA vaccine development, pulling $500 million in funding from projects, and voicing support for a shift to other vaccine platforms.\n• The company recently secured $153 million in series B funding, even amid a significant contraction in biotech investment, showing enthusiasm for the platform, Becraft said.\n• Over the next 10 to 15 years, this could lead to expanded opportunities with other companies.\n• It’s also testing the drug in phase 2 kidney cancer and bladder cancer, among others, according to a second-quarter update.\n• In May, Strand released promising interim phase 1 results for its lead candidate STX-001 in melanoma and other solid tumors." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/m/8ed7d118-5f72-3e00-b57e-fdc4bb36dfca/moderna-and-biontech.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>